Literature DB >> 21584766

Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.

Kim M Hemsley1, John J Hopwood.   

Abstract

Lysosomal storage disorders are inherited metabolic diseases in which a mutation in a gene encoding a lysosomal enzyme or lysosome-related protein results in the intra-cellular accumulation of substrate and reduced cell/tissue function. Few patients with neurodegenerative lysosomal storage disorders have access to safe and effective treatments although many therapeutic strategies have been or are presently being studied in vivo thanks to the availability of a large number of animal models. This review will describe the comparative advancement of a variety of therapeutic strategies through the 'research pipeline'. Our goal is to provide information for clinicians, researchers and patients/families alike on the leading therapeutic candidates at this point in time, and also to provide information on emerging approaches that may provide a safe and effective treatment in the future. The length of the pipeline represents the significant and sustained effort required to move a novel concept from the laboratory into the clinic.

Entities:  

Mesh:

Year:  2011        PMID: 21584766     DOI: 10.1007/s10545-011-9341-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  82 in total

1.  Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer.

Authors:  A Bosch; E Perret; N Desmaris; D Trono; J M Heard
Journal:  Hum Gene Ther       Date:  2000-05-20       Impact factor: 5.695

Review 2.  Genistein: a natural isoflavone with a potential for treatment of genetic diseases.

Authors:  Grzegorz Wegrzyn; Joanna Jakóbkiewicz-Banecka; Magdalena Gabig-Cimińska; Ewa Piotrowska; Magdalena Narajczyk; Anna Kloska; Marcelina Malinowska; Dariusz Dziedzic; Izabela Gołebiewska; Marta Moskot; Alicja Wegrzyn
Journal:  Biochem Soc Trans       Date:  2010-04       Impact factor: 5.407

Review 3.  A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.

Authors:  Jian-Qiang Fan
Journal:  Biol Chem       Date:  2008-01       Impact factor: 3.915

4.  Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice.

Authors:  T Ohashi; K Watabe; K Uehara; W S Sly; C Vogler; Y Eto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

6.  NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.

Authors:  Mylvaganam Jeyakumar; David A Smith; Ian M Williams; Mario Cortina Borja; David C A Neville; Terry D Butters; Raymond A Dwek; Frances M Platt
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

7.  Substrate reduction therapy in juvenile GM2 gangliosidosis.

Authors:  Gustavo H B Maegawa; Brenda L Banwell; Susan Blaser; Geoffrey Sorge; Maggie Toplak; Cameron Ackerley; Cynthia Hawkins; Jason Hayes; Joe T R Clarke
Journal:  Mol Genet Metab       Date:  2009-06-12       Impact factor: 4.797

8.  Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice.

Authors:  Adriana M Montaño; Hirotaka Oikawa; Shunji Tomatsu; Tatsuo Nishioka; Carole Vogler; Monica A Gutierrez; Toshihiro Oguma; Yun Tan; Jeffrey H Grubb; Vu Chi Dung; Amiko Ohashi; Ken-ichi Miyamoto; Tadao Orii; Yukio Yoneda; William S Sly
Journal:  Mol Genet Metab       Date:  2008-03-21       Impact factor: 4.797

9.  Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.

Authors:  Mark J Osborn; Ron T McElmurry; Brandon Peacock; Jakub Tolar; Bruce R Blazar
Journal:  Mol Ther       Date:  2008-06-03       Impact factor: 11.454

Review 10.  CNS-directed gene therapy for lysosomal storage diseases.

Authors:  Mark S Sands; Mark E Haskins
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

View more
  2 in total

1.  Glycobiology: Enzyme deficiencies deciphered.

Authors:  Lena Kjellén
Journal:  Nat Chem Biol       Date:  2012-01-18       Impact factor: 15.040

2.  Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders.

Authors:  Joseph J Orsini; Monica M Martin; Amanda L Showers; Olaf A Bodamer; X Kate Zhang; Michael H Gelb; Michele Caggana
Journal:  Clin Chim Acta       Date:  2012-04-21       Impact factor: 3.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.